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expertise, patient indication, institution guidelines and cultivated practice. Regional 
authorities reimburse chemotherapeutics according to different tariffs and codes. 
METHODS: A systematic literature review of the bibliographic databases Medline 
and Embase was performed. In addition, hand searching of reimbursement databases, 
national reimbursement tariffs and semi-structured interviews with expert oncologists 
were completed. Data extraction and evidence synthesis from these sources formed 
the basis for this evaluation. RESULTS: Fifty-nine publications (16 manuscripts, 29 
study protocols, 14 EMEA Public Assessment Reports) and nine expert interviews 
across four countries were included. The eight mNSCLC drugs and their seven com-
binations result in a wide set of administration patterns with variation in treatment 
schedules, number of interventions per patient, and difference in treatment settings in 
terms of inpatient versus outpatient approaches. Calculation of the 6 monthly admin-
istration cost of seven drug regimes for mNSCLC in France, Germany and Spain 
results in a range of a2,970 to a19,792, most affected by inpatient or outpatient 
administration setting. CONCLUSIONS: The following factors were found to result 
in variations in administration costs: setting (i.e. inpatient/outpatient); frequency of 
administration (e.g. weekly); duration of single administration (10–120 minutes); 
length of cycle (total number of administrations) type of cycle length (ﬁxed or ﬂexible); 
health care professional administering (e.g. nurse or physician); concomitant drugs 
(e.g. saline) and drug dosage. Together with differences in country-speciﬁc reimburse-
ment tariffs, these factors create signiﬁcant variation in administration patterns and 
costs associated with the delivery of drugs for mNSCLC.
CANCER – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the overall health-related quality of life (HRQL) of children 
diagnosed with ALL across major phases of therapy and identify areas for remediation. 
METHODS: All children registered in the trial at participating centres (n  5) and 5 
years of age at assessment were eligible. HRQL assessments were collected from 
parents using Health Utilities Index Mark 3 (HUI3) during 4 standard phases of 
therapy: induction (4 weeks); CNS prophylaxis (3); intensiﬁcation (30); continuation 
(71). Differences in mean HRQL utilities were tested using ANOVA for demographic 
(age and gender) and clinical factors: risk status; phase; and randomization group. 
Statistical signiﬁcance was p  0.05 with multiple-testing adjustments. Quality-
adjusted life years (QALYs) were calculated by phases for patients and general popula-
tion controls. Frequency distributions identiﬁed attributes affected. RESULTS: 600 
assessments were collected. Overall completion rate was 77%. Mean utilities differed 
(p  0.001) among phases: 0.67 induction; 0.75 CNS; 0.79 intensiﬁcation; 0.87 con-
tinuation. There were no differences in mean utilities for demographic or clinical 
factors. QALY estimates were, for patients and controls: 0.05 and 0.07 induction; 
0.04 and 0.05 CNS; 0.46 and 0.54 intensiﬁcation; 1.19 and 1.27 continuation. Most 
of the total QALY difference was from intensiﬁcation (42%) and continuation (42%). 
Pain was the HUI3 attribute most frequently affected among patients: 52% during 
intensiﬁcation and 37% during continuation. Combinations of HUI3 disabilities were 
common. During intensiﬁcation, 65% of patients with moderate/severe emotional 
disability also had moderate/severe pain. During continuation, 67% of patients with 
moderate/severe ambulation disability also had moderate/severe pain. CONCLU-
SIONS: The vast majority of QALYs lost by patients was associated with two phases 
of treatment and one health attribute. Future research to improve HRQL during 
treatment for ALL should focus on reducing pain during intensiﬁcation and continua-
tion phases.
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OBJECTIVES: There is a growing literature of health state utility values in oncology, 
providing researchers with an increasing opportunity to draw on existing published 
values rather than obtaining new data. A review of utility studies would identify 
existing values and gaps in the current literature. Our objective was to conduct a rapid, 
comprehensive literature review capturing oncology speciﬁc utilities and disutilities for 
adverse events, associated with therapeutic area of oncology, in order to develop a 
utilities library. METHODS: A comprehensive search string and pre-determined eli-
gibility criteria guided a search of Embase.com and the Cochrane Library focusing on 
primary papers and recent robust systematic reviews published from 1999–2009. To 
guide data extraction and construct the utility library, categories were created and 
included cancer type; treatment information; methods of utility capture; and utility/
disutility value/range. RESULTS: We identiﬁed 362 studies estimating utility and disu-
tility values in oncology, in a wide range of cancer types. Breast and prostate cancers 
were the most commonly investigated (n  91 and n  49 respectively). Comparably, 
a paucity of utility values were reported for other cancers. Methods of utility elicitation 
varied in robustness and wide-ranging values were reported. The most common 
method of utility capture was EQ5D followed by the HUI and the Time-Trade-Off or 
Standard Gamble techniques. Conversely, only 1 study employed the SF-6D. Although 
the most common causes of cancer-related deaths are lung and colorectal cancer, we 
found fewer studies eliciting utilities for these cancers relative to breast and prostate 
cancers (n  21 and n  27 respectively). CONCLUSIONS: This study demonstrates 
the value in reviewing literature estimating utilities and disutilities in oncology. It 
highlights areas in oncology where identiﬁed utility values may be combined to 
produce more robust values and examine sources of variation.
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OBJECTIVES: Given that treatments for chronic lymphocytic leukaemia (CLL) are 
palliative rather than curative, evaluating the patient-perceived impacts of therapy is 
critical. To date, no utility studies from the patient or general public perspective have 
been conducted in CLL. Thus, the objective of this study was to measure preferences 
for health states associated with CLL treatment. METHODS: This was a cross-sec-
tional study of 89 members of the general population in the UK (England and Scot-
land). Using standard gamble, each participant valued four health states describing 
response status, six describing treatment-related toxicities based on Common Toxicity 
Criteria, and two describing line of treatment. The health states incorporated stan-
dardized descriptions of treatment response (symptoms have “improved,” “stabi-
lized,” or “gotten worse”), swollen glands, impact on daily activities, fatigue, appetite, 
and night sweats. Utility estimates ranged from 0.0, reﬂecting dead, to 1.0, reﬂecting 
full health. RESULTS: Complete response (CR) was the most preferred health state 
(mean utility, 0.91), followed by partial response (PR), 0.84; no change (NC), 0.78; 
and progressive disease (PD), 0.68. Among the toxicity states, grade I/II nausea and 
nausea/vomiting had the smallest utility decrements (both were 0.05), and grade III/
IV pneumonia had the greatest decrement (-0.20). The utility decrements obtained for 
toxicity states can be subtracted from utilities for CR, PR, NC, and PD, as appropriate. 
The utilities for second- and third-line treatments, which are attempted when symp-
toms worsen, were 0.71 and 0.65, respectively. In general, the sample was well-
matched according to the age and sex distribution for the adult UK population. No 
signiﬁcant differences in utilities were observed by age, sex, or knowledge/experience 
with leukaemia. CONCLUSIONS: This study reports UK population utilities for a 
universal set of CLL health states that incorporate intended treatment response and 
unintended toxicities. These utilities can be applied in future cost-effectiveness analyses 
of CLL treatment.
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OBJECTIVES: Cancer patients’ preferences and assessment of the risks and beneﬁts 
associated with cancer therapy may inﬂuence their decisions to continue their treat-
ment and eventually determine their satisfaction with the outcomes of treatment. The 
main objective of this study was to validate a Korean translation of the Cancer 
Therapy Satisfaction Questionnaire (CTSQ) for use in Korea to assess expectation 
and satisfaction with the treatments of traditional Korean medicine and integrative 
cancer therapy, combined western and traditional Korean medicine (TKM) received. 
METHODS: To evaluate the conceptual equivalence and consistency of the items and 
scales, forward translation, reconciliations, backward translation, and focus group 
discussions were performed. After completing translation procedures, a pilot test was 
conducted for cognitive testing. The Korean translation of CTSQ was completed by 
14 cancer patients treated by Korean traditional medicine and 10 patients by integra-
tive cancer therapy. RESULTS: Of 14 patients with TKM only and 10 patients with 
integrative therapy, gender distributions were similar. The mean (/sd) age were 
53.2(/13.7) and 55.2(/10.7) years for the TKM only and Integrative therapy 
group, respectively. Most patients were stage 4 (88.9%). Cronbach’s alphas for the 
internal consistency reliability of three domains, Expectations of Therapy (ET), Feel-
ings about Side Effects (FSE), Satisfaction with Therapy (SWT) were 0.78, 0.68, and 
0.77, respectively. In the TKM group, mean scores of ET, FSE, and SWT domains 
were 81.8/16.6, 80.8/22.9, and 82.1/14.3, respectively, whereas in the integra-
tive therapy group, mean scores were 86.0/11.5, 76.9/21.3, and 77.0/12.3, 
respectively. CONCLUSIONS: These results support the applications of the Korean 
CTSQ for the ﬁeld test in full scale assessing treatment satisfaction associated with 
both integrative cancer therapy and a single traditional Korean medicine.
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OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an essen-
tial component of research methodology in preparation for multinational clinical 
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trials. One such measure is the FACT-Leukemia questionnaire (FACT-Leu), which 
evaluates the quality of life (QOL) of leukemia patients. METHODS: This study set 
out to linguistically validate the FACT-Leu for use in Argentina, Austria, Belgium, 
Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Egypt, Finland, 
France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithua-
nia, Malaysia, Mexico, The Netherlands, Norway, Poland, Romania, Russia, Serbia, 
Slovak Republic, Slovenia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, 
Ukraine and Venezuela. The study sample consisted of 758 patients (444 males/310 
females/4 missing) diagnosed with leukemia. Patient mean age was 47 years, and at 
the time of administration, 628 patients were receiving medical treatment. The sample 
consisted of patients who speak 43 languages collectively. The FACT-Leu was trans-
lated according to the standard FACIT methodology. Patients diagnosed with Leuke-
mia completed the respective translated questionnaire and then participated in a 
cognitive interview to determine if there were any problems with the translations or 
item content. Quantitative analyses (descriptive statistics and reliability analyses) were 
performed on the combined sample and participant comments were analyzed qualita-
tively in order to conﬁrm the validity of the translations. RESULTS: The FACT-Leu 
translations exhibited good internal reliability and linguistic validity. The alpha coef-
ﬁcient for the questionnaire as a whole including all languages was 0.96. Subscale 
alphas ranged from 0.81 to 0.91, also indicating good internal consistency. All items 
on the FACT-Leu correlated at an acceptable level. CONCLUSIONS: The FACT-Leu 
demonstrated acceptable reliability and linguistic validity in all 43 languages. We 
consider these translations acceptable for PRO assessment in international research 
and clinical trials.
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OBJECTIVES: Little is known about CAM use among prostate cancer patients. This 
study describes CAM use, patient factors that predicted CAM use, and satisfaction 
with CAM among men with local stage prostate cancer. METHODS: Newly diag-
nosed local stage prostate cancer patients in California and Washington State com-
pleted self-administered surveys. Patients were asked about sources of information 
they used to learn about prostate cancer, and at six months, about types of CAM they 
were using and satisfaction with those therapies. RESULTS: A total of 512 men 
completed baseline surveys before treatment and six-month follow-up surveys. 261 
(51%) reported using CAM at follow-up. The average age was 65; 69% were white, 
11% black, 10% Asian; 128 (49%) had “low risk” local stage prostate cancer by PSA 
and Gleason score. The most common forms of CAM utilized included personal prayer 
(n  148, 57%), herbs or dietary supplements (n  86, 33%), and special diets (n  
84, 32%). Fifty-one percent used one type of CAM, 26% used two, and 22% used 
three or more. In multivariate analysis, patients were signiﬁcantly more likely to use 
CAM if they had consulted medical literature (OR 1.96, CI 1.23–3.11) or talked with 
friends or family members (OR 1.76, CI 1.17–2.64). Prostate cancer risk group, 
comorbidities, age, race, education level, marital status, employment, and income were 
not signiﬁcantly associated with CAM use. Most described CAM as “very” or “some-
what” helpful” (92%). Many CAM users [43% (n  113)] did not discuss CAM with 
a health professional. CONCLUSIONS: In this multi-site study, more than half of all 
men with local stage prostate cancer reported using CAM. Race and education were 
not predictors of use. A substantial minority of CAM users did not discuss these 
treatments with their physician. Since no CAM approach has demonstrated beneﬁt 
for local stage prostate cancer, future research should examine men’s perceptions of 
the beneﬁts.
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OBJECTIVES: To review PRO labelling claims achieved in oncology in Europe and 
in the US and consider the beneﬁts, and challenges faced. METHODS: PROLabels 
database was searched to identify oncology products with PRO labeling approved in 
Europe since 1995 or in the US since 1998. FDA and EMEA websites and guidance 
documents were reviewed. PUBMED was searched for articles on PRO claims in 
oncology. RESULTS: Among all oncology products approved, 19 were identiﬁed with 
PRO claims; nine in the U.S, ﬁve in Europe, and ﬁve in both. The language used in 
the labelling was limited to beneﬁt (e.g. “. . . resulted in symptom beneﬁts by signiﬁ-
cantly prolonging time to deterioration in cough, dyspnoea, and pain, versus placebo”) 
and equivalence (e.g. “no statistical differences were observed between treatment 
groups for global QOL”). Seven products used a validated HRQL tool; two used 
symptom tools; two used both; seven used single-item symptom measures (one was 
unknown). The following emerged as likely reasons for success: ensuring systematic 
PRO data collection; clear rationale for pre-speciﬁed endpoints; adequately powered 
trials to detect differences and clinically signiﬁcant changes; adjusting for multiplicity; 
developing an a priori statistical analysis plan including primary and subgroup analy-
ses, dealing with missing data, pooling multiple-site data; establishing clinical versus 
statistical signiﬁcance; interpreting failure to detect change. End-stage patient drop-out 
rates and cessation of trials due to exceptional therapeutic beneﬁt pose signiﬁcant 
challenges to demonstrating treatment PRO improvement. CONCLUSIONS: PRO 
labelling claims demonstrate treatment impact and the trade-off between efﬁcacy and 
side effects ultimately facilitating product differentiation. Reliable and valid instru-
ments speciﬁc to the desired language, claim, and target population are required. 
Practical considerations include rationale for study endpoints, transparency in assump-
tions, and attention to subtle variations in data.
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OBJECTIVES: The identiﬁcation and management of unmet supportive care needs is 
an essential component of health care for people with cancer. The study aimed to 
evaluate the informative, psychological, social, and practical needs, focusing on infor-
mation needs over two consecutive (one-month) assessments. METHODS: The study 
was a longitudinal research. A total of 245 consecutive patients at IDI-IRCCS, Rome, 
were enrolled. They ﬁlled the Edmonton Symptom Assessment System (ESAS) and the 
Need Evaluation Questionnaire (NEQ) at baseline and one month later (n.115). The 
psychometric properties of questionnaires have been well documented in literature. 
ESAS is a questionnaire with 10 items describing cancer related symptoms in the visual 
analogue scales. NEQ is a standardized questionnaire for psychosocial needs. Multiple 
logistic regressions were used to examine the association between information needs 
and patient characteristics. RESULTS: Patients need more information about their 
own disease condition (preference information ranking: prognosis, treatment, exams, 
diagnosis). Patients with higher education (OR 2.20; p  0.052) need to be more 
informed about diagnosis and more involved in their therapeutic choices (OR 2.37; 
p  0.053). Women need physicians to be more sincere with them (OR 2.70; p  0.029). 
Patients, positive to the question on ESAS depression (cut off q7) believe they 
need more explanations about treatments (p  0.005), more comprehensible informa-
tion from health personnel (p  0.015), more sincerity (p  0.039) and more reassur-
ance by clinicians (p  0.007) compared to the negative ones.Still the information 
needs seem to be stable over time: 70 % of patients showed similar ranking at follow-
up. Patients with modiﬁed needs at the one-month assessment (30%) are equally 
divided into two groups. No statically signiﬁcant differences were observed between 
groups. CONCLUSIONS: The results of the study showed that monitoring patients 
understanding and preferences for information, in the complex process of patient-
physician communication, is relevant to tailor exhaustive explanation for each 
patient.
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OBJECTIVES: In a randomized, phase III trial, sunitinib showed superior progression-
free survival over interferon-alfa (IFN-A), 11 vs. 5 mo, respectively (P  0.001), as 
ﬁrst-line mRCC therapy; median overall survival with sunitinib was 2 years (Motzer, 
2009). Here, we report ﬁnal QOL results from this trial. METHODS: 750 treatment-
naïve mRCC patients were randomized 1:1 to receive sunitinib 50 mg orally once-daily 
in 6-week cycles (4 weeks on drug, 2 weeks off), or IFN-A 9 MU subcutaneously 
thrice-weekly. QOL was measured by 9 endpoints: Functional Assessment of Cancer 
Therapy–General (FACT-G), which has 4 subscales; FACT-Kidney Symptom Index–
15 item (FKSI-15), which includes a Disease-Related Symptoms (FKSI-DRS) subscale 
(primary QOL endpoint); and EQ-5D questionnaire’s utility index (EQ-5D Index) and 
visual analog scale (EQ-VAS). Higher scores indicated better outcomes. Patients com-
pleted questionnaires on days 1 and 28 of each cycle. Data were analyzed for the 
intent-to-treat population using mixed-effects models (MM), supplemented with 
pattern-mixture models (PMM). We also compared QOL of patients in the US and 
EU (France, Germany, Italy, Poland, Spain and UK). RESULTS: Patients on sunitinib 
reported better FKSI-15 and FKSI-DRS scores than those on IFN-A, with a signiﬁcant 
difference in overall means across cycles (4.06 and 2.36, respectively; P  0.0001; 
MM). Similarly, differences in means for FACT-G (and all subscales), EQ-5D Index, 
and EQ-VAS all signiﬁcantly favored sunitinib (P  0.05). Per pre-established thresh-
olds, between-treatment differences in mean scores were clinically meaningful for 
FKSI-15, FKSI-DRS, FACT-G, and the FACT-G functional well-being subscale. In the 
US, all endpoints, except the EQ-5D index score, signiﬁcantly favored sunitinib over 
IFN-A (P  0.05). In the EU, 5 of 9 endpoints signiﬁcantly favored sunitinib over 
IFN-A (P  0.05). Across all analyses, PMM and MM results were similar. CONCLU-
SIONS: Sunitinib provides superior QOL over IFN-A, in addition to superior efﬁcacy, 
as ﬁrst-line mRCC therapy, with similar ﬁndings in the US and EU.
